Compound Database

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.

A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.

An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.

A pentadecapeptide studied extensively in animal models for tendon, ligament, muscle, and gut healing. Human evidence remains limited.

A synthetic version of Thymosin Beta-4 studied in animal models for wound healing, tissue repair, and reduced inflammation.

A selective growth hormone secretagogue and ghrelin receptor agonist that stimulates pulsatile GH release with minimal effect on cortisol or prolactin.

A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.

An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.

A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.

The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.

A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.

An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.

A non-peptide, orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Completed but did not pass Phase 3 for approval.

A GHRH fragment historically approved as a diagnostic and pediatric GH agent, now used in compounded anti-aging research.

An early GH secretagogue hexapeptide that strongly stimulates growth hormone and appetite.

A long-acting analogue of IGF-1 studied in animal models for muscle growth and tissue repair.

A naturally occurring copper-binding tripeptide widely used in skincare and studied for wound healing and skin remodeling.

A synthetic heptapeptide approved in Russia for stroke and cognitive disorders, studied for BDNF-driven neuroprotection.

A synthetic anxiolytic peptide developed in Russia, studied for anxiety and mild cognitive effects without sedation.

A standardized mixture of neuropeptides used clinically in many countries for stroke, dementia, and TBI.

A synthetic tetrapeptide studied in Russian research for telomerase activation and effects on aging biomarkers.

An investigational mitochondria-targeting peptide studied for rare mitochondrial disease and age-related organ decline.

An immune-modulating thymic peptide approved in many countries for hepatitis and used as an immune adjuvant.

A thymus-derived peptide preparation studied in Russian research for restoring age-related immune decline.

An FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women.

An unapproved melanocortin agonist studied for skin pigmentation and libido, with notable safety concerns.

An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway.

An experimental senolytic peptide that selectively triggers death of senescent cells in animal studies.

The body's master intracellular antioxidant tripeptide, used to support redox balance, detoxification, and skin, with mixed clinical evidence for supplementation.

A glutathione precursor that is FDA-approved as a mucolytic and antidote for acetaminophen overdose, and studied more broadly in psychiatry and respiratory health.

A central metabolic coenzyme marketed via IV and injectable forms for anti-aging and recovery, with declining levels in aging but limited clinical proof for supplementation.

A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a contested regulatory status in the US.

A mitochondrial-derived peptide studied as an exercise mimetic that improves metabolic homeostasis and insulin sensitivity in animal models.

A mitochondrial-derived peptide studied for neuroprotection and metabolic health, found at higher levels in some long-lived populations.

A circulating TGF-beta family factor at the center of young-blood rejuvenation research, with contested and preliminary evidence.

A potent synthetic GH-releasing hexapeptide studied for growth hormone release and direct cardioprotective effects.

A second-generation GH secretagogue approved in Japan as a diagnostic agent, producing strong GH release with less appetite effect than GHRP-6.

A modified fragment of growth hormone developed for obesity that promotes fat metabolism in animals but failed to beat placebo in human weight-loss trials.

The lipolytic C-terminal fragment of growth hormone studied in animals for fat loss without growth-hormone-like effects on glucose or IGF-1.

An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and type 2 diabetes, with advanced trials in China.

An FDA-approved synthetic amylin analogue used with insulin to improve post-meal glucose control and reduce appetite.

An experimental peptide that targets the blood supply of white fat, causing dramatic weight loss in primates but with significant kidney toxicity.

A natural protein that blocks myostatin and activin, studied largely through gene therapy for muscle growth and muscular dystrophy.

A pegylated version of an IGF-1 splice variant studied in animals for muscle repair and satellite cell activation after damage.

A myostatin/activin decoy studied for muscular dystrophy whose trials were halted over vascular safety signals.

A naturally occurring actin-binding peptide studied for wound healing, cardiac repair, and eye conditions; the parent molecule of TB-500.

An EPO-derived peptide that activates tissue-protective repair signaling without raising red blood cells, studied for nerve pain in sarcoidosis.

A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.

An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.

The main human cathelicidin antimicrobial peptide, central to innate immunity and wound healing, with a complex double-edged role in disease.

An experimental angiotensin-derived peptide reported to be an extremely potent promoter of new synapse formation in animal models of cognition.

A small peptide derived from a neurotrophic factor studied for promoting new neuron growth and protecting against Alzheimer-like changes in animals.

An experimental peptide studied for rapid antidepressant effects and neurogenesis by blocking a potassium channel in the brain.

A proline-containing dipeptide nootropic approved in Russia, studied for mild cognitive impairment and neuroprotection.

An FDA-approved melanocortin agonist that increases skin pigmentation to protect people with a rare light-sensitivity disorder.

Synthetic gonadotropin-releasing hormone, historically approved for diagnosis and fertility and now used to preserve testicular function during testosterone therapy.

A reproductive neuropeptide that triggers the body's own GnRH release, studied for fertility, hypogonadism, and sexual response.

A natural hormone that is FDA-approved for labor and is also studied, with mixed results, for social, bonding, and psychiatric effects.

The body's own hunger hormone and the natural trigger for growth hormone release, and the template for the entire GHRP peptide class.

An early synthetic growth hormone releasing peptide, part of the first generation that established the GHRP class.

FDA-approved recombinant human growth hormone used for growth hormone deficiency and several other approved indications.

The natural hormone that switches off growth hormone release; its analogues like octreotide are approved drugs.

An investigational once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide, studied for obesity and diabetes.

An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control.

An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrition.

The natural gut hormone behind the entire GLP-1 drug class, released after eating to boost insulin and reduce appetite.

A natural gut hormone that promotes growth and repair of the intestinal lining, the basis for the drug teduglutide.

An investigational long-acting GLP-1 agonist that showed cardiovascular and kidney benefits in a large outcomes trial.

The hormone that raises blood sugar, FDA-approved as an emergency treatment for severe hypoglycemia and a target of the newest dual and triple agonists.

An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.

An experimental small-molecule enzyme inhibitor studied in animals for fat metabolism and muscle, popular on longevity resources.

A naturally occurring peptide studied for sleep, stress resilience, and pain, with limited and inconsistent human evidence.

A neuroprotective peptide fragment studied in humans for neurodegenerative disease, with a failed pivotal trial but ongoing interest.

A peptide derived from a neural cell adhesion molecule studied in animals for memory, plasticity, and neuroprotection.

A mixture of low-molecular-weight brain peptides used in Russia for stroke, brain injury, and cognitive disorders.

A short synthetic peptide bioregulator from the Khavinson group studied for brain protection and cognition.

A synthetic dipeptide immune modulator derived from thymus peptide research, used in Russia to support immune function.

A pentapeptide fragment of thymopoietin studied and used in some countries as an immune modulator.

A zinc-dependent thymic hormone studied for immune regulation, inflammation, and pain, mostly in preclinical work.

A synthetic dipeptide from the Khavinson bioregulator research studied for immune and anti-aging effects.

A synthetic peptide bioregulator studied in Russian research for cardiovascular tissue and age-related heart changes.

A signaling peptide with broad roles in immunity, inflammation, and blood flow, studied intranasally for chronic inflammatory conditions.

The natural melanocortin hormone behind skin pigmentation, appetite, and inflammation, and the template for melanotan and related peptides.

An FDA-approved gonadotropin used in fertility and to maintain testicular function and testosterone production in men.

The natural water-retention hormone, FDA-approved as a drug to raise blood pressure in critically ill patients.

An FDA-approved vasopressin analogue for diabetes insipidus, bedwetting, and certain bleeding disorders.

An FDA-approved long-acting somatostatin analogue used for acromegaly and hormone-secreting tumors.

An FDA-approved bone-building peptide, a fragment of parathyroid hormone used for severe osteoporosis.

An FDA-approved bone-building peptide analogue of parathyroid hormone-related protein for postmenopausal osteoporosis.

A hormone that lowers blood calcium, FDA-approved (as salmon calcitonin) for osteoporosis, Paget's disease, and high calcium.

An FDA-approved GnRH agonist that suppresses sex hormones, used for prostate cancer, endometriosis, and precocious puberty.

An FDA-approved GnRH agonist implant that suppresses sex hormones for prostate and breast cancer and endometriosis.

An FDA-approved GnRH antagonist used in fertility treatment to prevent premature ovulation.

A versatile antioxidant compound studied for diabetic nerve pain and metabolic health, sold as a supplement and used as a drug in some countries.

A diet-derived antioxidant amino acid that accumulates in cells via a dedicated transporter, studied as a possible longevity nutrient.

An amino-acid-derived compound essential for fat metabolism, FDA-approved for genuine deficiency and widely used for energy and recovery.

A topical cosmetic peptide marketed as a 'Botox-like' wrinkle reducer that relaxes expression lines at the skin surface.

A widely used topical skincare peptide that signals the skin to produce more collagen, studied for fine lines and firmness.

A topical cosmetic peptide extension of Argireline marketed for reducing the appearance of expression wrinkles.

An essential vitamin given by injection for deficiency and widely offered in wellness clinics for energy, though benefit without deficiency is limited.

A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.

Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.

Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.

Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight loss and is heading to Phase 3.

A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.

Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass.

A long-acting GLP-1 agonist in Phase 3 development, notable for the potential of extended, less frequent dosing.

Pfizer's oral small-molecule GLP-1 agonist whose development was discontinued after tolerability and safety signals.

A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.

A triple GLP-1, GIP, and glucagon agonist developed mainly for metabolic liver disease.

A well-studied vitamin B3 form and NAD+ precursor that reliably raises NAD+ levels in humans, widely used in longevity supplement stacks.

A gut-derived compound that triggers mitophagy and has improved muscle function in older adults in human trials, one of the better-evidenced longevity supplements.

A natural polyamine that induces autophagy, linked in population studies to lower mortality and studied for cardiovascular and cognitive aging.

A plant flavonoid and leading natural senolytic that clears senescent cells in animal studies and is now in human frailty trials.

A common dietary flavonoid used as a senolytic, most notably paired with the drug dasatinib in human senescence trials.

An FDA-approved leukemia drug repurposed in research as a senolytic, most often combined with quercetin to clear senescent cells.

An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.

A metabolite supplement studied for healthy aging, with an early human study suggesting a reduction in biological age markers.

A combination of glycine and NAC studied in older adults for restoring glutathione and improving multiple markers of aging.

An experimental 'exercise mimetic' that activates energy-metabolism pathways in animals, with no human data yet.

Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide.

An ultra-long-acting GLP-1 agonist with a roughly 15-day half-life built for once-monthly injection, the centerpiece of Pfizer's Metsera acquisition and now heading into ten Phase 3 trials.

Structure Therapeutics' once-daily oral small-molecule GLP-1 agonist that produced 16.3% placebo-adjusted weight loss at 44 weeks, the highest reported for any GLP-1 pill so far.

A once-weekly GLP-1/GIP dual agonist in the tirzepatide class that delivered 19.2% weight loss at 48 weeks in a Chinese Phase 3 trial and is now in global pivotal studies at higher doses.

Roche's signaling-biased GLP-1/GIP dual agonist that produced 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2, the strongest number in its class, with Phase 3 starting in 2026.

AstraZeneca's once-daily oral GLP-1 pill, 10.5% weight loss at 26 weeks in Phase 2b, now entering a broad Phase 3 program.

Novo Nordisk's licensed triple agonist that produced up to 19.7% weight loss in 24 weeks in a Chinese Phase 2, the company's answer to retatrutide.

Hengrui's once-daily oral GLP-1 pill with two positive Chinese Phase 3 trials (about 11% weight loss at 50 weeks), filed in China and in global Phase 2 through Kailera.

AstraZeneca's weekly amylin analog that jumped to Phase 3 in 2026 as a monotherapy and as an add-on to GLP-1 drugs, with detailed Phase 2 numbers still unpublished.

Pfizer's monthly amylin analog (from Metsera) with a 19-day half-life, being co-formulated with berobenatide into a once-monthly GLP-1 plus amylin combination.

An antibody that blocks the cannabinoid CB1 receptor outside the brain; alone it did little, but with semaglutide it reached 22.3% weight loss at 52 weeks and halved regain during a drug holiday.

Novo Nordisk's oral peripherally acting CB1 blocker: 7.1 kg weight loss in 16 weeks in Phase 2a, but with dose-related anxiety, irritability and sleep problems that Phase 2b must resolve.

Boehringer Ingelheim's first-in-class triple agonist that swaps glucagon for the NPY2 (PYY-type) satiety receptor, entering Phase 2 in July 2026 with no efficacy data yet.

An antibody against latent myostatin, under FDA review for spinal muscular atrophy (decision due September 30, 2026) and shown to preserve 55% of the lean mass otherwise lost on tirzepatide.

Regeneron's anti-myostatin antibody, alone or with the anti-activin antibody garetosmab, preserved 51% to 81% of lean mass during semaglutide weight loss in the COURAGE trial, at the cost of more adverse events.

Biohaven's anti-myostatin/activin fusion protein being tested as a standalone weight-loss drug, with a Phase 2 obesity readout expected in the second half of 2026.

The selective androgen receptor modulator known on the gray market as ostarine, now in formal trials where 3 mg cut lean-mass loss on semaglutide by 71% in adults over 60.

Scholar Rock's follow-on to apitegromab, engineered for self-injection alongside GLP-1 drugs; Phase 1 readout expected in the second half of 2026.

A weekly FGF21 analog that reversed cirrhosis in a subset of MASH patients at 96 weeks in Phase 2b, with three Phase 3 SYNCHRONY trials under way.

A glycoPEGylated FGF21 analog dosed weekly or every two weeks, now owned by Roche and in two Phase 3 MASH trials.

GSK's once-monthly FGF21 analog, acquired for $1.2 billion upfront, with FDA Breakthrough Therapy designation for MASH and Phase 2 results published in 2026.

An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end.

BioAge's brain-penetrant NLRP3 inhibitor that cut the inflammation marker hsCRP by a median 86% in two weeks in Phase 1, the strongest human anti-inflammaging signal from a geroscience company so far.

The most advanced senolytic in humans: an injected BCL-xL inhibitor that matched the biologic aflibercept on vision at most timepoints in a Phase 2b for diabetic macular edema.

Rubedo's topical senolytic that met its Phase 1 safety endpoint in psoriasis, eczema and photo-aged skin, with collagen gene expression rising in treated skin.

The first partial cellular reprogramming therapy in humans: Life Biosciences dosed the first patient in June 2026, delivering three Yamanaka factors to retinal cells to reverse epigenetic age in glaucoma and optic neuropathy.

The first clinical drug from Retro Biosciences, the Sam Altman-backed longevity company: an oral, brain-penetrant molecule meant to restore cellular clean-up (autophagy) for Alzheimer's and Parkinson's, in Phase 1 since December 2025.

The 'anti-aging gene' protein whose blood levels track with longevity and cognition; a gene therapy (KLTO-202) is heading toward human trials, while products sold online as 'klotho peptide' are not the protein studied.

A daily pill for senior dogs that could become the first drug the FDA has ever approved for extending lifespan; the agency accepted its safety and effectiveness packages in 2025 and 2026.

Roche's anti-amyloid antibody with a transferrin-receptor 'shuttle' that cleared amyloid in 91% of patients within seven months at a fraction of the ARIA seen with lecanemab or donanemab; Phase 3 started in 2025.

Lilly's next-generation, self-injected successor to donanemab that cleared amyloid in 75% of patients by six months in Phase 1, with a Phase 3 that completed in 2026.

An oral drug that lowers production of amyloid, tau and alpha-synuclein at once, now in an 850-patient Alzheimer's Phase 3 with a symptomatic readout due early 2027.

An oral IGF-1 metabolite mimic from the makers of trofinetide (Daybue), in the first-ever Phase 3 for Phelan-McDermid syndrome since February 2026.

A once-weekly prodrug of C-type natriuretic peptide, FDA-approved in February 2026 for achondroplasia in children aged two and older.

An injected Wnt-pathway small molecule for knee osteoarthritis, given once or twice a year, with an NDA submitted to the FDA in January 2026 after multi-year cartilage-preservation data.

An oral selective MC1R agonist, a small-molecule cousin of afamelanotide, that met its Phase 3 endpoint in the light-sensitivity disorder erythropoietic protoporphyria in January 2026.

Palatin's oral melanocortin-1 receptor agonist peptide for ulcerative colitis, with a small Phase 2 showing 33% remission versus 0% on placebo before the study was cut short for licensing.

A gray-market recombinant follistatin fragment marketed since late 2025 as a myostatin trap that builds muscle; there are no published studies, no pharmacokinetics and no safety data on the molecule itself.

The same 15 amino acid sequence as BPC-157 with an arginine salt instead of acetate, created as a compounding workaround; it has no studies of its own and inherits BPC-157's animal-only evidence.

A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation; no study has ever tested the combination, and GHK-Cu makes up most of the vial.

A three-peptide vendor blend (GHK-Cu, BPC-157, TB-500, typically 70 mg) marketed for skin and recovery; unstudied as a combination and mostly copper peptide by mass.

A 12 amino acid peptide discovered by AI-guided prohormone screening at Stanford that cut food intake by up to half in mice and minipigs through a non-GLP-1 pathway; no human trial exists.

An FDA-approved antidote for methemoglobinemia that biohackers take at low doses for mitochondrial energy and focus; the cognitive evidence is thin and it is a monoamine oxidase inhibitor with documented fatal interactions with antidepressants.

An oral AMPK activator with one 28-day human pilot in type 2 diabetes and recent mouse data, now sold as a research chemical and promoted as an exercise mimetic or metformin replacement.

The trans isomer of clomiphene, prescribed off-label through compounding to raise testosterone while preserving sperm production; never FDA-approved on its own after repeated complete response letters.

A 24 amino acid fragment of a load-induced IGF-1 splice variant, sold for local muscle repair; in-vitro and animal data only, with at least one failed replication and a half-life of minutes.

IGF-1 missing its first three amino acids, which stops binding proteins from holding it and makes it roughly ten times more potent but cleared in minutes; in-vitro and animal data only.

An aminosterol PTP1B inhibitor from dogfish shark that regenerated heart tissue in zebrafish and mice and caused fat-specific weight loss in obese mice; early human trials never produced published efficacy.

An approved eye drug that, injected into wounds in mice, produced regeneration without scars in a landmark 2021 Science paper; the first human scar trial started in June 2026, and off-label self-use carries days of severe photosensitivity.

A topical peptide that unblocks Wnt signaling in the scalp and stimulated hair regrowth and new follicle formation in mice; no human trial exists.

A Salk Institute fisetin derivative described as a 'geroneuroprotector' that improved memory and reduced brain lipid damage in mouse models of Alzheimer's; still in animal toxicology, yet already sold as a research chemical.

A mitochondria-targeted antioxidant registered in Russia as an eye drop for dry eye; rodent lifespan claims come from a single research group and oral systemic use has no human data.

A mitochondrial uncoupler that reversed obesity and insulin resistance in mice with a wider safety margin than DNP, now sold as a supplement-style research chemical with no human data.

A natural NAD+ precursor found in coffee and fenugreek that improved muscle function in aged mice and worms and is lower in people with sarcopenia; no human intervention trial yet.

The original 'exercise in a pill' from a 2008 Cell paper, an AMPK activator banned by WADA since 2009; human programs in heart surgery and leukemia failed to produce an approved drug, and effective animal doses are impractically large.

A PPAR-delta agonist that GSK abandoned in 2007 after long-term rodent studies produced cancers in multiple organs; still sold widely for endurance and fat loss despite the signal and a WADA ban.

A REV-ERB agonist marketed as an exercise mimetic; animal data only, very poor oral bioavailability, and published work questioning whether its effects even run through REV-ERB.

An in-vitro cancer-cell-lysing peptide sold online as a cancer cure in nebulized, injectable and other forms; the FDA warned the public after finding bacterial contamination in a product, and no human trial has ever been registered.

A four amino acid Khavinson bioregulator sold as the defined-sequence cousin of Cortexin for brain recovery; animal data from a single St. Petersburg group and no pharmacokinetics for any route.

A Khavinson tetrapeptide sold for lung and bronchial health; in-vitro work only, from one group, with no human trials or pharmacokinetics.

A Khavinson tetrapeptide sold for liver and gut 'bioregulation'; preclinical work from one group only.

A Khavinson tetrapeptide sold as a pancreatic bioregulator riding the metabolic-health wave; preclinical, single-group evidence only.

A Khavinson tripeptide sold for lung and mucosal health; patent-level and single-paper evidence.

A copper tripeptide marketed as the hair-growth cousin of GHK-Cu; in-vitro stimulation of hair follicle cells only, with no human trial.

The N-terminal four amino acids of thymosin beta-4, a natural anti-fibrotic peptide broken down by ACE (which is why ACE inhibitors raise it); animal and human observational data, sold as capsules unlikely to survive digestion.

A simplified relaxin analog that activates the RXFP1 receptor with a bias toward anti-fibrotic signaling; animal and cell data only.

The wakefulness neuropeptide, sold as a nasal spray for alertness after a primate study showed intranasal delivery reversed sleep-deprivation deficits; no human efficacy trial exists and approved narcolepsy drugs use small molecules instead.

A terminally modified analog of Semax sold as a more stable, longer-acting nasal spray; no published study of the amidate form exists, so its parent's Russian literature cannot be assumed to transfer.

A Russian orally active dipeptide anxiolytic acting on the cholecystokinin system, launched by Western vendors in 2026 as a non-sedating benzodiazepine alternative; single-group animal data only.